ITRM ITERUM THERAPEUTICS PLC Management Changes 8-K Filing 2024 - Appointment, Compliance, FDA Acknowledgment Iterum Therapeutics plc announces the appointment of a new Chief Medical Officer and the acceptance of a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1), as well as the acknowledgment of the resubmission of their new drug application by the FDA.Get access to all SEC 8-K filings of the ITERUM THERAPEUTICS PLC